Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

HITCHIPDIAG

Financiado

Rapid and Inexpensive Diagnosis of Heparin Induced Thrombocytopenia Using Glycan...

Rapid and Inexpensive Diagnosis of Heparin Induced Thrombocytopenia Using Glycan Arrays Containing Synthetic Glycosaminoglycans Rapid and Inexpensive Diagnosis of Heparin Induced Thrombocytopenia Using Glycan Arrays Containing Synthetic Glycosaminoglycans Heparin, a complex glycosaminoglycan (GAG) carbohydrate, is the most commonly used anticoagulant. Twel... ver más

30/09/2016

MPG

147K€

Presupuesto del proyecto: 147K€

Líder del proyecto

MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-09-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-PoC-2014: ERC Proof of Concept Grant

I+D

Cerrada hace 10 años

0% 100%

2 Participantes

MPG

147.09K€ | Lider

RED CONTROL SOCIEDAD LIMITAD...

426.07K€ | Participante

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2015-03-18
Fecha Fin: 2016-09-30

Presupuesto del proyecto 147K€

Descripción del proyecto Rapid and Inexpensive Diagnosis of Heparin Induced Thrombocytopenia Using Glycan Arrays Containing Synthetic Glycosaminoglycans Heparin, a complex glycosaminoglycan (GAG) carbohydrate, is the most commonly used anticoagulant. Twelve million patients in the EU are treated annually for conditions including acute coronary syndrome, deep-vein thrombosis and cardiopulmonary bypass surgery. Heparin-induced thrombocytopenia (HIT) is a dangerous adverse side effect of heparin administration. HIT-II develops after major surgery or dialysis and results in infarction, multi-organ failure and 20% mortality. In Europe 100,000 patients develop HIT-II annually. Currently, two HIT-II diagnostics are available. The HIPA and MAIPA tests detect antibodies against a complex of heparin and platelet factor 4 but suffer from low diagnostic specificity and accuracy. Faster, more reliable and cheaper methods to diagnose complications after administration of heparin are needed to improve patient wellbeing and reduce costs. The ERC Advanced grant AUTOHEPARIN yielded an instrument for the automated assembly of defined oligosaccharides. GAG glycan microarrays were produced by printing GAG oligosaccharides onto surfaces and used to screen patient blood. Specific glycan markers of high diagnostic value were discovered to detected HIT-II within minutes and reliabilities well above existing tests. The overall goal of the project is to establish the business model for a company that will focus on the production of GAG glycan arrays as HIT diagnostic. Specific activities include: 1) Development of standard protocols to detect HIT-II using GAG glycan microarray; 2) Plan and cost structure for GAG arrays production; 3) Analysis of the IP space and development of an IP strategy; 4) Evaluate potential markets and establish basis for commercial discussion with potential customers; 5) Prepare business plan for discussions with investors; 6) Incorporate company to commercialize GAG arrays as HIT diagnostic

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores